Galligioni E - Search Results

1

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.

Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, Fratino L, Gernone A, De Vivo R, Pappagallo GL, Galligioni E. Caffo O, et al. Among authors: galligioni e. Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284. Future Oncol. 2015. PMID: 25760977 Clinical Trial.

2

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.

Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, Sacco C, Valduga F, Cetto G, Galligioni E. Caffo O, et al. Among authors: galligioni e. BJU Int. 2008 Nov;102(9):1080-5. doi: 10.1111/j.1464-410X.2008.07779.x. Epub 2008 May 15. BJU Int. 2008. PMID: 18485028 Clinical Trial.

3

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone.

Caffo O, Sava T, Comploj E, Giampaolo MA, Segati R, Valduga F, Cetto G, Galligioni E. Caffo O, et al. Among authors: galligioni e. Urol Oncol. 2010 Mar-Apr;28(2):152-6. doi: 10.1016/j.urolonc.2008.07.033. Epub 2008 Oct 10. Urol Oncol. 2010. PMID: 18848786 Clinical Trial.

4

Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.

Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, Sacco C, Veccia A, Galligioni E. Caffo O, et al. Among authors: galligioni e. BJU Int. 2011 Dec;108(11):1825-32. doi: 10.1111/j.1464-410X.2011.10277.x. Epub 2011 May 26. BJU Int. 2011. PMID: 21615854 Clinical Trial.

5

Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.

Caffo O, Fratino L, Barbieri R, Perin A, Martini T, Sava T, Segati R, Vaccher E, Bernardo Bassan F, Veccia A, Pappagallo G, Galligioni E. Caffo O, et al. Among authors: galligioni e. Urol Oncol. 2013 Feb;31(2):180-6. doi: 10.1016/j.urolonc.2010.11.012. Epub 2011 Jul 31. Urol Oncol. 2013. PMID: 21803618 Clinical Trial.

6

Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.

Caffo O, Gernone A, Ortega C, Sava T, Cartenì G, Facchini G, Re GL, Amadio P, Bortolus R, Pagliarulo V, Prati V, Veccia A, Galligioni E. Caffo O, et al. Among authors: galligioni e. J Neurooncol. 2012 Mar;107(1):191-6. doi: 10.1007/s11060-011-0734-y. Epub 2011 Oct 12. J Neurooncol. 2012. PMID: 21989810

7

Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.

Caffo O, Pappagallo G, Brugnara S, Caldara A, di Pasquale MC, Ferro A, Frisinghelli M, Murgia V, Russo LM, Soini B, Valduga F, Veccia A, Galligioni E. Caffo O, et al. Among authors: galligioni e. Urology. 2012 Mar;79(3):644-9. doi: 10.1016/j.urology.2011.11.043. Urology. 2012. PMID: 22386418

8

Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.

Caffo O, Veccia A, Russo L, Galligioni E. Caffo O, et al. Among authors: galligioni e. Future Oncol. 2012 Dec;8(12):1585-95. doi: 10.2217/fon.12.156. Future Oncol. 2012. PMID: 23231520 Review.

9

Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.

Caffo O, Palermo A, Veccia A, Maines F, Chierichetti F, Berruti A, Galligioni E. Caffo O, et al. Among authors: galligioni e. Urology. 2013 Nov;82(5):1090-3. doi: 10.1016/j.urology.2013.07.029. Epub 2013 Aug 31. Urology. 2013. PMID: 24001702

10

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Pia Brizzi M, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Procopio G, et al. Among authors: galligioni e. Future Oncol. 2014 Aug;10(10):1741-50. doi: 10.2217/fon.14.48. Epub 2014 Mar 18. Future Oncol. 2014. PMID: 24641206 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176 results

Search Page